Cortexyme to Participate at 4th International Conference on Porphyromonas gingivalis and Related Species in Oral and Systemic Diseases

Author's Avatar
May 12, 2022

Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company pioneering therapeutic approaches to improve the lives of patients diagnosed with degenerative diseases, announced that the company will participate at The+4%3Csup%3Eth%3C%2Fsup%3E+International+Conference+on%3Ci%3E+Porphyromonas+gingivalis%3C%2Fi%3E+and+Related+Species+in+Oral+and+Systemic+Diseases (PgLouisville2022) taking place May 15-17, 2022 in Louisville, Kentucky. Cortexyme’s clinical advisory board member Mark Ryder, D.M.D., will provide an overview of GAIN Trial results and biomarker data examining the role of P. gingivalis in oral and systemic diseases.